Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2005
09/22/2005CA2559328A1 Resistance-repellent retroviral protease inhibitors
09/22/2005CA2559175A1 Composition; use of a composition and a method for treating obesity
09/22/2005CA2559143A1 Novel cycloalkyl-containing 5-acylindolinones, their preparation and their use as pharmaceutical products
09/22/2005CA2559139A1 Novel alkyl-containing 5-acylindolinones, their preparation and their use as pharmaceutical products
09/22/2005CA2559115A1 Novel aryl-containing 5-acylindolinones, the production thereof and their use as medicaments
09/22/2005CA2559069A1 Axon regeneration promoter
09/22/2005CA2559060A1 Phospholipases, nucleic acids encoding them and methods for making and using them
09/22/2005CA2558899A1 Fused ring azadecalin glucocorticoid receptor modulators
09/22/2005CA2558893A1 Vla-4 antagonists
09/22/2005CA2558771A1 Multiple promoter expression cassettes for simultaneous delivery of rnai agents
09/22/2005CA2558766A1 The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
09/22/2005CA2558582A1 Stabilised supersaturated solids of lipophilic drugs
09/22/2005CA2558552A1 Sulphonylpyrroles as hdac inhibitors
09/22/2005CA2558393A1 Compositions comprising drospirenone molecularly dispersed
09/22/2005CA2558391A1 Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
09/22/2005CA2558390A1 Novel thio-containing hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
09/22/2005CA2558249A1 Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
09/22/2005CA2558243A1 Inhibitors of histone deacetylase
09/22/2005CA2558219A1 Poorly water-soluble drug-containing solid formulation
09/22/2005CA2558214A1 Ion channel modulators
09/22/2005CA2558036A1 Substituted hydroxyethylamine aspartyl protease inhibitors
09/22/2005CA2558034A1 Substituted hydroxyethylamine aspartyl protease inhibitors
09/22/2005CA2557926A1 Hiv integrase inhibitors
09/22/2005CA2557672A1 Ion channel modulators
09/22/2005CA2557665A1 Ion channel modulators
09/22/2005CA2557650A1 Ion channel modulators
09/22/2005CA2557648A1 Ion channel modulators
09/22/2005CA2557642A1 Ion channel modulators
09/22/2005CA2557633A1 Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics
09/22/2005CA2557545A1 Substituted 5,12-diaza-benzoanthracene analogues
09/22/2005CA2557527A1 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
09/22/2005CA2557479A1 Biphenyl compounds useful as muscarinic receptor antagonists
09/22/2005CA2557307A1 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
09/22/2005CA2557247A1 Compounds as inhibitors of hepatitis c virus ns3 serine protease
09/22/2005CA2557005A1 Antineoplastic combinations of cci-779 and rituximab
09/22/2005CA2556826A1 Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
09/22/2005CA2556223A1 Synergistic effect of compositions comprising carotenoids selected from lutein, beta-carotene and lycopene
09/22/2005CA2555914A1 Therapeutic modulation of ppar (gamma) activity
09/22/2005CA2555867A1 Arylalkylamino-substituted quinazoline analogues
09/22/2005CA2555250A1 Anti-infectious hydrogel compositions
09/22/2005CA2554554A1 Novel dicationic imidazo[1,2-a]pyridines and 5,6,7,8-tetrahydro-imidazo[1,2a]pyridines as antiprotozoal agents
09/22/2005CA2554547A1 Particulate plant sterol compositions
09/22/2005CA2542023A1 Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
09/22/2005CA2499220A1 Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury
09/21/2005EP1577322A1 Novel proteins and use thereof
09/21/2005EP1577317A1 Nitrogen-containing heterocycic derivatives, medicinal compositions containing the same and medicinal use thereof
09/21/2005EP1577315A1 Process for producing hop glume polyphenol
09/21/2005EP1577311A1 Salts of a pyridazino aquinoline derivative and use for the treatment of pain
09/21/2005EP1577309A1 Optically active dihydropyridine derivative
09/21/2005EP1577308A2 Non-steroidal polycyclic ring sulphamate derivatives, their preparation and their use as oestrone sulphatase inhibitors
09/21/2005EP1577302A1 Novel ethylenediamine derivatives
09/21/2005EP1577301A1 Diamine derivatives
09/21/2005EP1577298A1 Process for determining the purity of amlodipine
09/21/2005EP1577297A1 Process for the production of atorvastatin calcium in amorphous form
09/21/2005EP1577296A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their use
09/21/2005EP1577295A1 Process for preparing 2-oxo-1-pyrrolidine derivatives as intermediates
09/21/2005EP1577294A1 S-substituted n-1- (hetero)aryl alkyl-n - (hetero)aryl alkylysothiocarbamides, method for the production thereof, physiologically active s-substituted n-1- (hetero )aryl alkyl-n - (hetero)aryl alkylysothiocarbamides,a pharmaceutical compound and curing method
09/21/2005EP1577292A1 Phenylaminoethanol derivatives as beta2 receptor agonists
09/21/2005EP1577291A1 Phenylethanolamine derivatives as beta-2 agonists
09/21/2005EP1577288A1 Selective estrogen receptor modulators
09/21/2005EP1576986A2 Sustained-release tramadol formulations with 24-hour clinical efficacy
09/21/2005EP1576985A1 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
09/21/2005EP1576970A1 Intraluminal device with a coating containing a therapeutic agent
09/21/2005EP1576962A1 Composition comprising isovaleramide and ibuprofen
09/21/2005EP1576961A1 Pharmaceutical compound containing silymarin and carbopol, production method thereof and use of same as a regenerator of tissue and pancreatic cells with endogenous secretion damaged by diabetes mellitus
09/21/2005EP1576960A1 Composition containing green and yellow vegetables and light-colored vegetables
09/21/2005EP1576959A1 A coixenolide capsules for treating prostate disease
09/21/2005EP1576958A1 An composition containing triterpenoid saponins extracted from bamboo, and the preparation method and use thereof
09/21/2005EP1576956A2 Chromium/biotin treatment of type II diabetes
09/21/2005EP1576955A1 Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR) 1,3a,8 trimethyl 1,2,3,3a,8,8a hexahydropyrrolo[2,3 b]indol 5 yl phenylcarbamate
09/21/2005EP1576954A1 Preferential inhibition of release of pro-inflammatory cytokines
09/21/2005EP1576953A1 Propofol-containing fat emulsions
09/21/2005EP1576894A1 The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and Metabolic Syndrome
09/21/2005EP1576893A1 Composition containing isoflavone of high purity at high concentration and process for producing the same
09/21/2005EP1576892A1 Method for obtaining a physiological tannin extract from banana trees and the use thereof as food complement
09/21/2005EP1576179A2 Methods and compositions for inducing apoptosis in cancer cells
09/21/2005EP1576176A2 Short interfering nucleic acid hybrids and methods thereof
09/21/2005EP1576168A2 Therapeutic polypeptides nucleic acids encoding same and methods of use
09/21/2005EP1576160A2 Borrelidin-producing polyketide synthase and its use
09/21/2005EP1576159A1 The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
09/21/2005EP1576138A2 2-branched nucleosides and flaviviridae mutation
09/21/2005EP1576118A2 ALLELE-SPECIFIC siRNA-MEDIATED GENE SILENCING
09/21/2005EP1576110A2 Cell migration inhibiting compositions and methods and compositions for treating cancer
09/21/2005EP1576100A2 Purified composition of bispecific molecules and methods of production
09/21/2005EP1576093A2 3-deoxyglucosone and skin
09/21/2005EP1576092A2 Compounds and methods
09/21/2005EP1575993A2 Methods for treating patients and identifying therapeutics
09/21/2005EP1575982A1 Promoter for the production of hyaluronic acid containing ginsenoside compound k
09/21/2005EP1575981A1 Angiogenic compounds and uses thereof
09/21/2005EP1575976A2 Methods and compositions for therapeutic use of rna interference
09/21/2005EP1575973A2 Substitution derivatives of n sp 6 sp -benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds
09/21/2005EP1575970A2 10-substituted macrolide antibiotics
09/21/2005EP1575969A1 SUBSTITUTED 9A-N-{N - 4-(SULFONYL)PHENYL CARB AMOYL} DERIVATIVES OF 9-DEOXO-9-DIHYDRO-9A-AZA-9A-HOMOERITHROMYCIN A AND 5-0-DESOSAMINYL--9-DEOXO-9-DI-HYDRO-9A-AZA-9A-HO MOERITHRONOLIDE A
09/21/2005EP1575966A1 Therapeutic quinazoline derivatives
09/21/2005EP1575964A2 N-(benzyl)aminoalkyl carboxylate, phosphinates, phosphonates and tetrazoles as edg receptor agonists
09/21/2005EP1575959A2 Compositions useful as inhibitors of protein kinases
09/21/2005EP1575955A1 Pyrrolobenzodiazepines
09/21/2005EP1575953A1 Anhydrous crystalline form of valacyclovir hydrochloride
09/21/2005EP1575946A1 Quinazoline compounds
09/21/2005EP1575944A1 Oxazolidinone derivatives as antibacterial agents
1 ... 4534 4535 4536 4537 4538 4539 4540 4541 4542 4543 4544 4545 4546 4547 4548 4549 4550 4551 4552 4553 4554 ... 7860